The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Columba study update: subcutaneous daratumumab in R/R MM
Saad Usmani, MD, FACP, Levine Cancer Institute, Charlotte, NC, gives an update on the COLUMBA study (NCT03277105), a randomized, open-label, phase III trial evaluating the efficacy and safety of subcutaneous (SC) versus intravenous (IV) daratumumab in patients with relapsed/refractory (R/R) multiple myeloma (MM). With longer follow-up, data continues to support that SC and IV administration of daratumumab have similar safety profiles, however, SC administration has a reduced treatment burden due to a shorter administration duration. This interview was recorded at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
